NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits

PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients

GALWAY, Ireland, Oct. 10, 2025 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced positive two-year results from the PARAGON clinical study, published in Ear, Nose, & Throat Journal. The data confirm that treatment with Neurent Medical's NEUROMARK System, a radiofrequency ablation device indicated for chronic rhinitis, provides durable, clinically meaningful improvements in symptoms and quality of life for patients with both allergic and nonallergic rhinitis.

Key 2-Year Efficacy Findings

• The mean reflective Total Nasal Symptom Score (rTNSS) improved by 55% from baseline at 2 years (p<.0001).
• 76% of participants achieved the responder rate (≥30% reduction in rTNSS).
• 91% achieved the minimum clinically important difference (MCID) of ≥1 point reduction in rTNSS.
• All 4 rTNSS subscores (congestion, rhinorrhea, sneezing, and itching) and postnasal drip and cough demonstrated sustained and significant improvement through 2 years (p<.0001).
• The Nasal Obstruction Symptom Evaluation (NOSE) score and all 5 subscores remained significantly improved at 2 years (p<.0001).
• Quality of life, as measured by the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), showed durable benefit, with 79% of participants achieving MCID (≥0.4-point reduction).
• The Eustachian Tube Dysfunction Questionnaire (ETDQ-7) also demonstrated significant long-term improvement (p<.0001).
• Both allergic and nonallergic rhinitis subgroups had durable and significant improvement in rTNSS, NOSE, mini-RQLQ, and ETDQ-7 at 2 years, with no significant differences between groups.

"These long-term results provide robust evidence that NEUROMARK offers durable relief for patients suffering from chronic rhinitis, addressing not only nasal symptoms but also postnasal drip, cough, and ear-related complaints," said Dr. David Yen, MD, lead author of the publication. "The consistency of improvements through two years underscores the potential for NEUROMARK to be a transformative therapy for this difficult-to-treat condition."

"We are delighted to share these 2-year results, which build upon the strong 6-month findings and confirm the sustained efficacy and safety of our NEUROMARK System," said Brian Shields, CEO of Neurent Medical. "This milestone reinforces our mission to deliver innovative, minimally invasive solutions that improve patients' lives and provide ENT physicians with effective tools to manage chronic rhinitis."

About the NEUROMARK System

The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency lesions to disrupt posterior nasal nerves in patients with chronic rhinitis. By gently applying controlled low-power RF energy, the system disrupts parasympathetic nerve signaling to reduce the inflammatory response and alleviate symptoms such as congestion and rhinorrhea.

About Neurent Medical

Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target multiple nerve branches in a single procedure. Headquartered in Galway, Ireland, with U.S. operations in Braintree, MA, Neurent Medical is backed by leading venture capital investors.

SOURCE Neurent Medical